RYBREVANT
Total Payments
$4.7M
Transactions
14,029
Doctors
6,299
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.1M | 10,048 | 5,097 |
| 2023 | $883,847 | 2,042 | 1,213 |
| 2022 | $637,871 | 1,431 | 845 |
| 2021 | $64,048 | 508 | 393 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 14 | 47.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $915,108 | 350 | 19.4% |
| Consulting Fee | $898,108 | 528 | 19.0% |
| Food and Beverage | $355,374 | 11,680 | 7.5% |
| Travel and Lodging | $182,248 | 633 | 3.9% |
| Space rental or facility fees (teaching hospital only) | $86,600 | 27 | 1.8% |
| Education | $58,622 | 797 | 1.2% |
Payments by Type
General
$2.5M
14,015 transactions
Research
$2.2M
14 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Rolfo_A Phase II of Amivantamab in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with high MET amplification (Lung-MAP Sub-Study) | Janssen Research & Development, LLC | $763,013 | 0 |
| A Phase II of Amivantamab in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with high MET amplification (Lung-MAP Sub-Study) | Janssen Research & Development, LLC | $562,956 | 0 |
| A Phase I/II Study of Amivantamab carboplatin and paclitaxel in Recurrent Metastatic Head and Neck Cancer | Janssen Research & Development, LLC | $443,026 | 0 |
| A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors | Janssen Research & Development, LLC | $156,646 | 0 |
| Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants with Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination with Tyrosine Kinase Inhibitors | Janssen Research & Development, LLC | $86,861 | 0 |
Top Doctors Receiving Payments for RYBREVANT
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Diego, CA | $2.3M | 78 |
| , MD | Internal Medicine | Los Angeles, CA | $201,155 | 248 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Altamonte Springs, FL | $150,661 | 180 |
| , MD | Hematology & Oncology | Orlando, FL | $148,602 | 116 |
| , MD | Hematology & Oncology | Cincinnati, OH | $145,216 | 160 |
| , D.O | Medical Oncology | Delray Beach, FL | $93,202 | 112 |
| , MD | Hematology & Oncology | Detroit, MI | $90,766 | 93 |
| , M.D | Medical Oncology | Sacramento, CA | $46,957 | 59 |
| , MD | Hematology | Kansas City, MO | $45,529 | 48 |
| , M.D | Medical Oncology | Fairfax, VA | $44,101 | 58 |
| , M.D | Hematology & Oncology | New York, NY | $37,747 | 33 |
| , MD, MPH, MBA | Hematology & Oncology | Chicago, IL | $36,795 | 36 |
| , MD | Hematology & Oncology | Fort Lauderdale, FL | $34,073 | 52 |
| , MD | Medical Oncology | Los Angeles, CA | $25,431 | 18 |
| , MD | Internal Medicine | Seattle, WA | $21,164 | 21 |
| , M.D | Internal Medicine | Houston, TX | $20,036 | 25 |
| , M.D | Specialist | Boston, MA | $19,848 | 22 |
| , M.D | Hematology & Oncology | San Diego, CA | $18,706 | 13 |
| , MD | Hematology & Oncology | New Orleans, LA | $18,381 | 25 |
| , M.D | Hematology | New Orleans, LA | $17,927 | 15 |
| , M.D | Anatomic Pathology & Clinical Pathology | West Hollywood, CA | $17,346 | 19 |
| , MD | Hematology & Oncology | Portland, OR | $17,168 | 17 |
| , M.D | Medical Oncology | Bethesda, MD | $15,051 | 24 |
| , MD | Medical Oncology | Duarte, CA | $13,921 | 19 |
| , M.D | Medical Oncology | Boston, MA | $13,892 | 11 |
Ad
Manufacturing Companies
- Janssen Research & Development, LLC $2.2M
- Janssen Biotech, Inc. $2.0M
- Janssen Scientific Affairs, LLC $442,448
- Janssen Global Services, LLC $70,436
- Janssen Pharmaceuticals, Inc $9,490
- Johnson & Johnson Health Care Systems Inc. $859.81
Product Information
- Type Drug
- Total Payments $4.7M
- Total Doctors 6,299
- Transactions 14,029
About RYBREVANT
RYBREVANT is a drug associated with $4.7M in payments to 6,299 healthcare providers, recorded across 14,029 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Research & Development, LLC.
Payment data is available from 2021 to 2024. In 2024, $3.1M was paid across 10,048 transactions to 5,097 doctors.
The most common payment nature for RYBREVANT is "Unspecified" ($2.2M, 47.1% of total).
RYBREVANT is associated with 5 research studies, including "Rolfo_A Phase II of Amivantamab in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with high MET amplification (Lung-MAP Sub-Study)" ($763,013).